This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Patients aged > 18 and ≤ 80 years of age;
Can be treated with the study drug within 24 h of symptom onset;
No fever or infection was observed upon admission;
NIHSS score ≥10;
Infections within the last 4 weeks;
Use of antibiotics within the last 2 weeks;
Known pre-ICH dysphagia;
Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;